Esperion Therapeutics Inc. [ESPR] moved down -1.00: Why It’s Important

Esperion Therapeutics Inc. [NASDAQ: ESPR] closed the trading session at $3.98 on 03/15/23. The day’s price range saw the stock hit a low of $3.865, while the highest price level was $4.05. The company report on March 8, 2023 that International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk.

– International Lipid Expert Group Recommends Earlier Utilization of Bempedoic Acid in Both Secondary Prevention Patients As Well As in Patients with Partial or Complete Statin Intolerance – .

– Following the “Lower Is Better For Longer” Approach to Lipid Management, the Recently Published Paper Provides Evidence-Based Guidance on Using Bempedoic Acid in Atherosclerotic Cardiovascular Disease (ASCVD), Heterozygous Familial Hypercholesterolemia (HeFH) and Statin Intolerance – .

The stocks have a year to date performance of -36.12 percent and weekly performance of -20.56 percent. The stock has been moved at -43.55 percent over the last six months. The stock has performed -29.06 percent around the most recent 30 days and changed -25.88 percent over the most recent 3-months.

If compared to the average trading volume of 2.15M shares, ESPR reached to a volume of 3803298 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Esperion Therapeutics Inc. [ESPR]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ESPR shares is $11.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ESPR stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Credit Suisse have made an estimate for Esperion Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 07, 2023. While these analysts kept the previous recommendation, BofA Securities raised their target price to Neutral. The new note on the price target was released on February 27, 2023, representing the official price target for Esperion Therapeutics Inc. stock. Previously, the target price had yet another raise to $12, while Jefferies analysts kept a Buy rating on ESPR stock.

The Average True Range (ATR) for Esperion Therapeutics Inc. is set at 0.43, with the Price to Sales ratio for ESPR stock in the period of the last 12 months amounting to 4.26.

ESPR stock trade performance evaluation

Esperion Therapeutics Inc. [ESPR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -20.56. With this latest performance, ESPR shares dropped by -29.06% in over the last four-week period, additionally sinking by -43.55% over the last 6 months – not to mention a drop of -16.03% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ESPR stock in for the last two-week period is set at 25.14, with the RSI for the last a single of trading hit 19.51, and the three-weeks RSI is set at 29.50 for Esperion Therapeutics Inc. [ESPR]. The present Moving Average for the last 50 days of trading for this stock 6.01, while it was recorded at 4.33 for the last single week of trading, and 6.62 for the last 200 days.

Esperion Therapeutics Inc. [ESPR]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Esperion Therapeutics Inc. [ESPR] shares currently have an operating margin of -237.83 and a Gross Margin at +63.61. Esperion Therapeutics Inc.’s Net Margin is presently recorded at -309.58.

Esperion Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.30 and a Current Ratio set at 2.70.

Earnings per share (EPS) analysis for Esperion Therapeutics Inc. [ESPR] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ESPR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Esperion Therapeutics Inc. go to 16.90%.

Esperion Therapeutics Inc. [ESPR]: Insider Ownership positions

There are presently around $293 million, or 87.80% of ESPR stock, in the hands of institutional investors. The top three institutional holders of ESPR stocks are: WASATCH ADVISORS INC with ownership of 6,848,378, which is approximately -8.236% of the company’s market cap and around 0.60% of the total institutional ownership; BLACKROCK INC., holding 5,509,187 shares of the stock with an approximate value of $21.93 million in ESPR stocks shares; and MEDITOR GROUP LTD, currently with $17.79 million in ESPR stock with ownership of nearly 0% of the company’s market capitalization.

105 institutional holders increased their position in Esperion Therapeutics Inc. [NASDAQ:ESPR] by around 21,301,391 shares. Additionally, 66 investors decreased positions by around 10,935,453 shares, while 23 investors held positions by with 41,483,368 shares. The mentioned changes placed institutional holdings at 73,720,212 shares, according to the latest SEC report filing. ESPR stock had 46 new institutional investments in for a total of 10,176,975 shares, while 26 institutional investors sold positions of 4,808,184 shares during the same period.